Financing ·
Files prospectus supplement to sell up to $79.99M of common stock under ATM agreement with Jefferies
ATYRaTYR PHARMA Inc
aTyr Pharma filed a prospectus supplement with the SEC to offer and sell shares of its common stock having an aggregate offering price of up to $79,994,251 from time to time. The offering is conducted pursuant to the Company's Open Market Sale Agreement SM dated April 22, 2022, as amended on December 23, 2024, with Jefferies LLC acting as sales agent. This prospectus supplement was filed under the Company’s shelf registration statement on Form S-3 (File No. 333-289360), which was declared effective on August 18, 2025. The filing includes a legal opinion from Cooley LLP regarding the legality of the shares issuable under the agreement. aTyr Pharma is a biopharmaceutical company focused on developing therapies for rare genetic diseases.